APO Research
Talk to an analyst

APO RESEARCH · REPORT

Adult and Pediatric Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Adult and Pediatric Vaccines Market Analysis and Forecast 2026-2032

22 December 2025195 pages

Choose your research edition.

Industry ResearchAdult and Pediatric Vaccines Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Adult and Pediatric Vaccines Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Adult and Pediatric Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Adult and Pediatric Vaccines Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Adult and Pediatric Vaccines Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Adult and Pediatric Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Adult and Pediatric Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Adult and Pediatric Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Adult and Pediatric Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Adult and Pediatric Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Adult and Pediatric Vaccines include Sanofi, Johnson and Johnson, Novartis, Merck, Pfizer, GlaxoSmithKline, Sinovac Biotech, AstraZeneca and Takeda Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Adult and Pediatric Vaccines, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Adult and Pediatric Vaccines, also provides the revenue of main regions and countries. Of the upcoming market potential for Adult and Pediatric Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Adult and Pediatric Vaccines revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Adult and Pediatric Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Adult and Pediatric Vaccines revenue, projected growth trends, production technology, application and end-user industry.

Adult and Pediatric Vaccines Segment by Company

Sanofi

Johnson and Johnson

Novartis

Merck

Pfizer

GlaxoSmithKline

Sinovac Biotech

AstraZeneca

Takeda Pharmaceutical

LG Life Sciences

Bavarian Nordic

Adult and Pediatric Vaccines Segment by Type

Adult Vaccines

Pediatric Vaccines

Adult and Pediatric Vaccines Segment by Application

Hospitals

Medical Care Centers

Others

Adult and Pediatric Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adult and Pediatric Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Adult and Pediatric Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adult and Pediatric Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Adult and Pediatric Vaccines in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Adult and Pediatric Vaccines company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Adult and Pediatric Vaccines revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Adult and Pediatric Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Adult Vaccines Major Player Table 3. Pediatric Vaccines Major Player Table 4. Global Adult and Pediatric Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospitals Major Player Table 6. Medical Care Centers Major Player Table 7. Others Major Player Table 8. Adult and Pediatric Vaccines Industry Trends Table 9. Adult and Pediatric Vaccines Industry Drivers Table 10. Adult and Pediatric Vaccines Industry Opportunities and Challenges Table 11. Adult and Pediatric Vaccines Industry Restraints Table 12. Global Adult and Pediatric Vaccines Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Adult and Pediatric Vaccines Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Adult and Pediatric Vaccines Market Share by Region (2021-2026) Table 15. Global Adult and Pediatric Vaccines Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Adult and Pediatric Vaccines Market Share by Region (2027-2032) Table 17. Global Adult and Pediatric Vaccines Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Adult and Pediatric Vaccines Revenue Market Share by Players (2021-2026) Table 19. Global Adult and Pediatric Vaccines Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Adult and Pediatric Vaccines Key Players Headquarters & Area Served Table 21. Global Adult and Pediatric Vaccines Players, Product Type & Application Table 22. Global Adult and Pediatric Vaccines Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Adult and Pediatric Vaccines by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Adult and Pediatric Vaccines Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Adult and Pediatric Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Adult and Pediatric Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Adult and Pediatric Vaccines Revenue Market Share by Type (2021-2026) Table 29. Global Adult and Pediatric Vaccines Revenue Market Share by Type (2027-2032) Table 30. Global Adult and Pediatric Vaccines Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Adult and Pediatric Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Adult and Pediatric Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Adult and Pediatric Vaccines Revenue Market Share by Application (2021-2026) Table 34. Global Adult and Pediatric Vaccines Revenue Market Share by Application (2027-2032) Table 35. Sanofi Company Information Table 36. Sanofi Business Overview Table 37. Sanofi Adult and Pediatric Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Sanofi Adult and Pediatric Vaccines Product Portfolio Table 39. Sanofi Recent Development Table 40. Johnson and Johnson Company Information Table 41. Johnson and Johnson Business Overview Table 42. Johnson and Johnson Adult and Pediatric Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Johnson and Johnson Adult and Pediatric Vaccines Product Portfolio Table 44. Johnson and Johnson Recent Development Table 45. Novartis Company Information Table 46. Novartis Business Overview Table 47. Novartis Adult and Pediatric Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Novartis Adult and Pediatric Vaccines Product Portfolio Table 49. Novartis Recent Development Table 50. Merck Company Information Table 51. Merck Business Overview Table 52. Merck Adult and Pediatric Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Merck Adult and Pediatric Vaccines Product Portfolio Table 54. Merck Recent Development Table 55. Pfizer Company Information Table 56. Pfizer Business Overview Table 57. Pfizer Adult and Pediatric Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Pfizer Adult and Pediatric Vaccines Product Portfolio Table 59. Pfizer Recent Development Table 60. GlaxoSmithKline Company Information Table 61. GlaxoSmithKline Business Overview Table 62. GlaxoSmithKline Adult and Pediatric Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. GlaxoSmithKline Adult and Pediatric Vaccines Product Portfolio Table 64. GlaxoSmithKline Recent Development Table 65. Sinovac Biotech Company Information Table 66. Sinovac Biotech Business Overview Table 67. Sinovac Biotech Adult and Pediatric Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Sinovac Biotech Adult and Pediatric Vaccines Product Portfolio Table 69. Sinovac Biotech Recent Development Table 70. AstraZeneca Company Information Table 71. AstraZeneca Business Overview Table 72. AstraZeneca Adult and Pediatric Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. AstraZeneca Adult and Pediatric Vaccines Product Portfolio Table 74. AstraZeneca Recent Development Table 75. Takeda Pharmaceutical Company Information Table 76. Takeda Pharmaceutical Business Overview Table 77. Takeda Pharmaceutical Adult and Pediatric Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Takeda Pharmaceutical Adult and Pediatric Vaccines Product Portfolio Table 79. Takeda Pharmaceutical Recent Development Table 80. LG Life Sciences Company Information Table 81. LG Life Sciences Business Overview Table 82. LG Life Sciences Adult and Pediatric Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. LG Life Sciences Adult and Pediatric Vaccines Product Portfolio Table 84. LG Life Sciences Recent Development Table 85. Bavarian Nordic Company Information Table 86. Bavarian Nordic Business Overview Table 87. Bavarian Nordic Adult and Pediatric Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Bavarian Nordic Adult and Pediatric Vaccines Product Portfolio Table 89. Bavarian Nordic Recent Development Table 90. North America Adult and Pediatric Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 91. North America Adult and Pediatric Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 92. North America Adult and Pediatric Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 93. North America Adult and Pediatric Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 94. North America Adult and Pediatric Vaccines Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. North America Adult and Pediatric Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 96. North America Adult and Pediatric Vaccines Revenue by Country (US$ Million) & (2027-2032) Table 97. Europe Adult and Pediatric Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 98. Europe Adult and Pediatric Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 99. Europe Adult and Pediatric Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 100. Europe Adult and Pediatric Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 101. Europe Adult and Pediatric Vaccines Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 102. Europe Adult and Pediatric Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 103. Europe Adult and Pediatric Vaccines Revenue by Country (US$ Million) & (2027-2032) Table 104. China Adult and Pediatric Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 105. China Adult and Pediatric Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 106. China Adult and Pediatric Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 107. China Adult and Pediatric Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 108. Asia Adult and Pediatric Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 109. Asia Adult and Pediatric Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 110. Asia Adult and Pediatric Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 111. Asia Adult and Pediatric Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 112. Asia Adult and Pediatric Vaccines Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 113. Asia Adult and Pediatric Vaccines Revenue by Region (US$ Million) & (2021-2026) Table 114. Asia Adult and Pediatric Vaccines Revenue by Region (US$ Million) & (2027-2032) Table 115. SAMEA Adult and Pediatric Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 116. SAMEA Adult and Pediatric Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 117. SAMEA Adult and Pediatric Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 118. SAMEA Adult and Pediatric Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 119. SAMEA Adult and Pediatric Vaccines Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. SAMEA Adult and Pediatric Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 121. SAMEA Adult and Pediatric Vaccines Revenue by Country (US$ Million) & (2027-2032) Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Adult and Pediatric Vaccines Image Figure 2. Global Adult and Pediatric Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Adult and Pediatric Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 4. Adult Vaccines Image Figure 5. Pediatric Vaccines Image Figure 6. Global Adult and Pediatric Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Adult and Pediatric Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospitals Image Figure 9. Medical Care Centers Image Figure 10. Others Image Figure 11. Global Adult and Pediatric Vaccines Market Size (US$ Million) & (2021-2032) Figure 12. Global Adult and Pediatric Vaccines Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Adult and Pediatric Vaccines Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Adult and Pediatric Vaccines Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Adult and Pediatric Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Adult and Pediatric Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Adult and Pediatric Vaccines Revenue Market Share by Type (2021-2032) Figure 19. Global Adult and Pediatric Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Adult and Pediatric Vaccines Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Adult and Pediatric Vaccines Revenue Market Share by Application (2021-2032) Figure 22. North America Adult and Pediatric Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Adult and Pediatric Vaccines Revenue Share by Type (2021-2032) Figure 24. North America Adult and Pediatric Vaccines Revenue Share by Application (2021-2032) Figure 25. North America Adult and Pediatric Vaccines Revenue Share by Country (2021-2032) Figure 26. United States Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Adult and Pediatric Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Adult and Pediatric Vaccines Revenue Share by Type (2021-2032) Figure 31. Europe Adult and Pediatric Vaccines Revenue Share by Application (2021-2032) Figure 32. Europe Adult and Pediatric Vaccines Revenue Share by Country (2021-2032) Figure 33. Germany Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Adult and Pediatric Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Adult and Pediatric Vaccines Revenue Share by Type (2021-2032) Figure 43. China Adult and Pediatric Vaccines Revenue Share by Application (2021-2032) Figure 44. Asia Adult and Pediatric Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Adult and Pediatric Vaccines Revenue Share by Type (2021-2032) Figure 46. Asia Adult and Pediatric Vaccines Revenue Share by Application (2021-2032) Figure 47. Asia Adult and Pediatric Vaccines Revenue Share by Region (2021-2032) Figure 48. Japan Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Adult and Pediatric Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Adult and Pediatric Vaccines Revenue Share by Type (2021-2032) Figure 56. SAMEA Adult and Pediatric Vaccines Revenue Share by Application (2021-2032) Figure 57. SAMEA Adult and Pediatric Vaccines Revenue Share by Country (2021-2032) Figure 58. Brazil Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Adult and Pediatric Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Adult Vaccines
  • Pediatric Vaccines
Applications
  • Hospitals
  • Medical Care Centers
  • Others
Companies covered
  • Sanofi
  • Johnson and Johnson
  • Novartis
  • Merck
  • Pfizer
  • GlaxoSmithKline
  • Sinovac Biotech
  • AstraZeneca
  • Takeda Pharmaceutical
  • LG Life Sciences
  • Bavarian Nordic

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Adult and Pediatric Vaccines Market by Type
  3. 1.2.1 Global Adult and Pediatric Vaccines Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Adult Vaccines
  5. 1.2.3 Pediatric Vaccines
  6. 1.3 Adult and Pediatric Vaccines Market by Application
  7. 1.3.1 Global Adult and Pediatric Vaccines Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospitals
  9. 1.3.3 Medical Care Centers
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Adult and Pediatric Vaccines Market Dynamics
  1. 2.1 Adult and Pediatric Vaccines Industry Trends
  2. 2.2 Adult and Pediatric Vaccines Industry Drivers
  3. 2.3 Adult and Pediatric Vaccines Industry Opportunities and Challenges
  4. 2.4 Adult and Pediatric Vaccines Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Adult and Pediatric Vaccines Market Perspective (2021-2032)
  2. 3.2 Global Adult and Pediatric Vaccines Growth Trends by Region
  3. 3.2.1 Global Adult and Pediatric Vaccines Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Adult and Pediatric Vaccines Market Size by Region (2021-2026)
  5. 3.2.3 Global Adult and Pediatric Vaccines Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Adult and Pediatric Vaccines Revenue by Players
  2. 4.1.1 Global Adult and Pediatric Vaccines Revenue by Players (2021-2026)
  3. 4.1.2 Global Adult and Pediatric Vaccines Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Adult and Pediatric Vaccines Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Adult and Pediatric Vaccines Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Adult and Pediatric Vaccines Key Players Headquarters & Area Served
  7. 4.4 Global Adult and Pediatric Vaccines Players, Product Type & Application
  8. 4.5 Global Adult and Pediatric Vaccines Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Adult and Pediatric Vaccines Market CR5 and HHI
  11. 4.6.3 2025 Adult and Pediatric Vaccines Tier 1, Tier 2, and Tier 3
5 Adult and Pediatric Vaccines Market Size by Type
  1. 5.1 Global Adult and Pediatric Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Adult and Pediatric Vaccines Revenue by Type (2021-2032)
  3. 5.3 Global Adult and Pediatric Vaccines Revenue Market Share by Type (2021-2032)
6 Adult and Pediatric Vaccines Market Size by Application
  1. 6.1 Global Adult and Pediatric Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Adult and Pediatric Vaccines Revenue by Application (2021-2032)
  3. 6.3 Global Adult and Pediatric Vaccines Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi Adult and Pediatric Vaccines Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi Adult and Pediatric Vaccines Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 Johnson and Johnson
  8. 7.2.1 Johnson and Johnson Company Information
  9. 7.2.2 Johnson and Johnson Business Overview
  10. 7.2.3 Johnson and Johnson Adult and Pediatric Vaccines Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Johnson and Johnson Adult and Pediatric Vaccines Product Portfolio
  12. 7.2.5 Johnson and Johnson Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Adult and Pediatric Vaccines Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Adult and Pediatric Vaccines Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Merck
  20. 7.4.1 Merck Company Information
  21. 7.4.2 Merck Business Overview
  22. 7.4.3 Merck Adult and Pediatric Vaccines Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Merck Adult and Pediatric Vaccines Product Portfolio
  24. 7.4.5 Merck Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Adult and Pediatric Vaccines Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Adult and Pediatric Vaccines Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 GlaxoSmithKline
  32. 7.6.1 GlaxoSmithKline Company Information
  33. 7.6.2 GlaxoSmithKline Business Overview
  34. 7.6.3 GlaxoSmithKline Adult and Pediatric Vaccines Revenue and Gross Margin (2021-2026)
  35. 7.6.4 GlaxoSmithKline Adult and Pediatric Vaccines Product Portfolio
  36. 7.6.5 GlaxoSmithKline Recent Developments
  37. 7.7 Sinovac Biotech
  38. 7.7.1 Sinovac Biotech Company Information
  39. 7.7.2 Sinovac Biotech Business Overview
  40. 7.7.3 Sinovac Biotech Adult and Pediatric Vaccines Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Sinovac Biotech Adult and Pediatric Vaccines Product Portfolio
  42. 7.7.5 Sinovac Biotech Recent Developments
  43. 7.8 AstraZeneca
  44. 7.8.1 AstraZeneca Company Information
  45. 7.8.2 AstraZeneca Business Overview
  46. 7.8.3 AstraZeneca Adult and Pediatric Vaccines Revenue and Gross Margin (2021-2026)
  47. 7.8.4 AstraZeneca Adult and Pediatric Vaccines Product Portfolio
  48. 7.8.5 AstraZeneca Recent Developments
  49. 7.9 Takeda Pharmaceutical
  50. 7.9.1 Takeda Pharmaceutical Company Information
  51. 7.9.2 Takeda Pharmaceutical Business Overview
  52. 7.9.3 Takeda Pharmaceutical Adult and Pediatric Vaccines Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Takeda Pharmaceutical Adult and Pediatric Vaccines Product Portfolio
  54. 7.9.5 Takeda Pharmaceutical Recent Developments
  55. 7.10 LG Life Sciences
  56. 7.10.1 LG Life Sciences Company Information
  57. 7.10.2 LG Life Sciences Business Overview
  58. 7.10.3 LG Life Sciences Adult and Pediatric Vaccines Revenue and Gross Margin (2021-2026)
  59. 7.10.4 LG Life Sciences Adult and Pediatric Vaccines Product Portfolio
  60. 7.10.5 LG Life Sciences Recent Developments
  61. 7.11 Bavarian Nordic
  62. 7.11.1 Bavarian Nordic Company Information
  63. 7.11.2 Bavarian Nordic Business Overview
  64. 7.11.3 Bavarian Nordic Adult and Pediatric Vaccines Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Bavarian Nordic Adult and Pediatric Vaccines Product Portfolio
  66. 7.11.5 Bavarian Nordic Recent Developments
8 North America
  1. 8.1 North America Adult and Pediatric Vaccines Revenue (2021-2032)
  2. 8.2 North America Adult and Pediatric Vaccines Revenue by Type (2021-2032)
  3. 8.2.1 North America Adult and Pediatric Vaccines Revenue by Type (2021-2026)
  4. 8.2.2 North America Adult and Pediatric Vaccines Revenue by Type (2027-2032)
  5. 8.3 North America Adult and Pediatric Vaccines Revenue Share by Type (2021-2032)
  6. 8.4 North America Adult and Pediatric Vaccines Revenue by Application (2021-2032)
  7. 8.4.1 North America Adult and Pediatric Vaccines Revenue by Application (2021-2026)
  8. 8.4.2 North America Adult and Pediatric Vaccines Revenue by Application (2027-2032)
  9. 8.5 North America Adult and Pediatric Vaccines Revenue Share by Application (2021-2032)
  10. 8.6 North America Adult and Pediatric Vaccines Revenue by Country
  11. 8.6.1 North America Adult and Pediatric Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Adult and Pediatric Vaccines Revenue by Country (2021-2026)
  13. 8.6.3 North America Adult and Pediatric Vaccines Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Adult and Pediatric Vaccines Revenue (2021-2032)
  2. 9.2 Europe Adult and Pediatric Vaccines Revenue by Type (2021-2032)
  3. 9.2.1 Europe Adult and Pediatric Vaccines Revenue by Type (2021-2026)
  4. 9.2.2 Europe Adult and Pediatric Vaccines Revenue by Type (2027-2032)
  5. 9.3 Europe Adult and Pediatric Vaccines Revenue Share by Type (2021-2032)
  6. 9.4 Europe Adult and Pediatric Vaccines Revenue by Application (2021-2032)
  7. 9.4.1 Europe Adult and Pediatric Vaccines Revenue by Application (2021-2026)
  8. 9.4.2 Europe Adult and Pediatric Vaccines Revenue by Application (2027-2032)
  9. 9.5 Europe Adult and Pediatric Vaccines Revenue Share by Application (2021-2032)
  10. 9.6 Europe Adult and Pediatric Vaccines Revenue by Country
  11. 9.6.1 Europe Adult and Pediatric Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Adult and Pediatric Vaccines Revenue by Country (2021-2026)
  13. 9.6.3 Europe Adult and Pediatric Vaccines Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Adult and Pediatric Vaccines Revenue (2021-2032)
  2. 10.2 China Adult and Pediatric Vaccines Revenue by Type (2021-2032)
  3. 10.2.1 China Adult and Pediatric Vaccines Revenue by Type (2021-2026)
  4. 10.2.2 China Adult and Pediatric Vaccines Revenue by Type (2027-2032)
  5. 10.3 China Adult and Pediatric Vaccines Revenue Share by Type (2021-2032)
  6. 10.4 China Adult and Pediatric Vaccines Revenue by Application (2021-2032)
  7. 10.4.1 China Adult and Pediatric Vaccines Revenue by Application (2021-2026)
  8. 10.4.2 China Adult and Pediatric Vaccines Revenue by Application (2027-2032)
  9. 10.5 China Adult and Pediatric Vaccines Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Adult and Pediatric Vaccines Revenue (2021-2032)
  2. 11.2 Asia Adult and Pediatric Vaccines Revenue by Type (2021-2032)
  3. 11.2.1 Asia Adult and Pediatric Vaccines Revenue by Type (2021-2026)
  4. 11.2.2 Asia Adult and Pediatric Vaccines Revenue by Type (2027-2032)
  5. 11.3 Asia Adult and Pediatric Vaccines Revenue Share by Type (2021-2032)
  6. 11.4 Asia Adult and Pediatric Vaccines Revenue by Application (2021-2032)
  7. 11.4.1 Asia Adult and Pediatric Vaccines Revenue by Application (2021-2026)
  8. 11.4.2 Asia Adult and Pediatric Vaccines Revenue by Application (2027-2032)
  9. 11.5 Asia Adult and Pediatric Vaccines Revenue Share by Application (2021-2032)
  10. 11.6 Asia Adult and Pediatric Vaccines Revenue by Country
  11. 11.6.1 Asia Adult and Pediatric Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Adult and Pediatric Vaccines Revenue by Country (2021-2026)
  13. 11.6.3 Asia Adult and Pediatric Vaccines Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Adult and Pediatric Vaccines Revenue (2021-2032)
  2. 12.2 SAMEA Adult and Pediatric Vaccines Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Adult and Pediatric Vaccines Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Adult and Pediatric Vaccines Revenue by Type (2027-2032)
  5. 12.3 SAMEA Adult and Pediatric Vaccines Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Adult and Pediatric Vaccines Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Adult and Pediatric Vaccines Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Adult and Pediatric Vaccines Revenue by Application (2027-2032)
  9. 12.5 SAMEA Adult and Pediatric Vaccines Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Adult and Pediatric Vaccines Revenue by Country
  11. 12.6.1 SAMEA Adult and Pediatric Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Adult and Pediatric Vaccines Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Adult and Pediatric Vaccines Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst